|
|
 Previous Article | Table of Contents | Next Article 
K562 cells produce and respond to human erythroid-potentiating activity
BR Avalos, SE Kaufman, M Tomonaga, RE Williams, DW Golde and JC Gasson
Department of Medicine, UCLA School of Medicine.
Human erythroid-potentiating activity (EPA) is a 28,000 mol wt glycoprotein
that stimulates the growth of erythroid progenitors in vitro and enhances
colony formation by the K562 human erythroleukemia cell line. EPA has
potent protease inhibitory activity, and is also referred to as tissue
inhibitor of metalloproteinases (TIMP). We observed that colony formation
by K562 cells in semi-solid medium containing reduced fetal calf serum
(FCS) is not directly proportional to the number of cells plated,
suggesting production of autostimulatory factors by K562 cells. Using
radioimmunoprecipitation and a bioassay for EPA, medium conditioned by K562
cells was found to contain high levels of biologically active EPA; Northern
hybridization analysis confirmed the expression of EPA mRNA. Radiolabeled
EPA was used to identify cell surface receptors on K562 cells. Together,
these results suggest that EPA may act as an autocrine growth factor for
K562 cells.
Volume 71,
Issue 6,
pp. 1720-1725,
06/01/1988
Copyright © 1988 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Verstappen and J.W. Von den Hoff
Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease.
J. Dent. Res.,
December 1, 2006;
85(12):
1074 - 1084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Verstappen and J.W. Von den Hoff
Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease
Journal of Dental Research,
December 1, 2006;
85(12):
1074 - 1084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S O Wurtz, A-S Schrohl, N M. Sorensen, U Lademann, I J Christensen, H Mouridsen, and N Brunner
Tissue inhibitor of metalloproteinases-1 in breast cancer
Endocr. Relat. Cancer,
June 1, 2005;
12(2):
215 - 227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Aalinkeel, M. P. N. Nair, G. Sufrin, S. D. Mahajan, K. C. Chadha, R. P. Chawda, and S. A. Schwartz
Gene Expression of Angiogenic Factors Correlates with Metastatic Potential of Prostate Cancer Cells
Cancer Res.,
August 1, 2004;
64(15):
5311 - 5321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-S. Rhee, R. Diaz, L. Korets, J. G. Hodgson, and L. M. Coussens
TIMP-1 Alters Susceptibility to Carcinogenesis
Cancer Res.,
February 1, 2004;
64(3):
952 - 961.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Gakiopoulou, L. Nakopoulou, A. Siatelis, I. Mavrommatis, E. G. Panayotopoulou, I. Tsirmpa, C. Stravodimos, and A. Giannopoulos
Tissue Inhibitor of Metalloproteinase-2 as a Multifunctional Molecule of Which the Expression Is Associated with Adverse Prognosis of Patients with Urothelial Bladder Carcinomas
Clin. Cancer Res.,
November 15, 2003;
9(15):
5573 - 5581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Oelmann, H. Herbst, M. Zuhlsdorf, O. Albrecht, A. Nolte, C. Schmitmann, O. Manzke, V. Diehl, H. Stein, and W. E. Berdel
Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells
Blood,
January 1, 2002;
99(1):
258 - 267.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. Durkan, J. E. Nutt, P. H. Rajjayabun, D. E. Neal, J. Lunec, and J. K. Mellon
Prognostic Significance of Matrix Metalloproteinase-1 and Tissue Inhibitor of Metalloproteinase-1 in Voided Urine Samples from Patients with Transitional Cell Carcinoma of the Bladder
Clin. Cancer Res.,
November 1, 2001;
7(11):
3450 - 3456.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Kadri, E. Petitfrère, C. Boudot, J.-M. Freyssinier, S. Fichelson, P. Mayeux, H. Emonard, W. Hornebeck, B. Haye, and C. Billat
Erythropoietin Induction of Tissue Inhibitors of Metalloproteinase-1 Expression and Secretion Is Mediated by Mitogen-activated Protein Kinase and Phosphatidylinositol 3-kinase Pathways
Cell Growth Differ.,
November 1, 2000;
11(11):
573 - 580.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
G. Li, R. Fridman, and H.-R. C. Kim
Tissue Inhibitor of Metalloproteinase-1 Inhibits Apoptosis of Human Breast Epithelial Cells
Cancer Res.,
December 1, 1999;
59(24):
6267 - 6275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Ries, F. Loher, C. Zang, M. G. Ismair, and P. E. Petrides
Matrix Metalloproteinase Production by Bone Marrow Mononuclear Cells from Normal Individuals and Patients with Acute and Chronic Myeloid Leukemia or Myelodysplastic Syndromes
Clin. Cancer Res.,
May 1, 1999;
5(5):
1115 - 1124.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Moses
The Regulation of Neovascularization by Matrix Metalloproteinases and Their Inhibitors
Stem Cells,
May 1, 1997;
15(3):
180 - 189.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. Stetler-Stevenson, A. Mansoor, M. Lim, P. Fukushima, J. Kehrl, G. Marti, K. Ptaszynski, J. Wang, and W. G. Stetler-Stevenson
Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Reactive and Neoplastic Lymphoid Cells
Blood,
March 1, 1997;
89(5):
1708 - 1715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T Hayakawa, K Yamashita, E Ohuchi, and A Shinagawa
Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2)
J. Cell Sci.,
January 9, 1994;
107(9):
2373 - 2379.
[Abstract]
[PDF]
|
|
|
|
|
